Eli Lilly: Jaypirca Achieves Fourth Phase 3 CLL Success Lilly's Jaypirca met its primary endpoint. The drug demonstrated fixed-duration efficacy. This marks its fourth positive Phase 3 readout. It strengthens Jaypirca's competitive position. Eli Lilly announced Jaypirca (pirtobrutinib) successfully met its primary endpoint in a fourth Phase 3 trial for chronic lymphocytic leukemia (CLL). The trial, BRUIN CLL-322, evaluated Jaypirca as a fixed-duration treatment. This is an industry first for the drug in CLL, demonstrating efficacy in a defined treatment period. The specific metric triggering this event was progression-free survival (PFS) superiority. This positive outcome bolsters Jaypirca's regulatory profile. The FDA previously granted accelerated approval for Jaypirca in mantle cell lymphoma (MCL) and CLL/SLL. This new data supports potential full approval and label expansion for fixed-duration use in CLL. Lilly will now prepare a supplemental New Drug Application (sNDA) for submission to the FDA, likely referencing 21 CFR Part 314.50 for content and format. EMA submission will follow. The success intensifies competition in the BTK inhibitor market. Jaypirca, a non-covalent BTK inhibitor, now poses a stronger challenge to established drugs like AbbVie/Janssen's Imbruvica and AstraZeneca's Calquence. This fixed-duration option could differentiate Jaypirca, offering a new treatment paradigm. Lilly anticipates sNDA submission by Q3 2026.